IRIDEX is excited to announce a major milestone in our growth journey with the successful raising of $10,000,000 in fresh funding. As a worldwide leader in the development and manufacturing of innovative light-based medical systems and delivery devices, we are committed to pushing the boundaries of technology to treat glaucoma and retinal diseases. This substantial investment reaffirms the confidence our investors have in our vision and underlines our commitment to providing superior technology that delivers superior results. With our comprehensive technical, clinical, and service support programs, we have built lasting relationships with healthcare providers, ensuring that our customers receive unmatched assistance every step of the way.
The funds will be strategically deployed to accelerate the advancement of our existing product lineup, including renowned devices like the Cyclo G6 glaucoma laser, IQ 577 retinal laser, IQ 532 retinal laser, and the innovative TxCell scanning laser delivery device. In addition, expanding our research and development capabilities will drive new breakthroughs in light-based medical procedures, reinforcing our industry-leading position. Our current direct sales operations in the United States and Germany, along with a robust network of approximately 70 independent distributors across over 100 countries, will enable us to capture emerging markets and serve more patients worldwide.
This exciting funding round not only bolsters our financial strength but also fuels our relentless pursuit of excellence in patient care and technological innovation. As we move forward, we remain dedicated to transforming the landscape of eye care and delivering tangible improvements in the quality of life for patients around the globe. Learn more about our innovations and future plans at iridex.com.
